




Supplementary Figure 1. End of treatment changes in PROs in patients adherent and not adherent to (A) IFN+RBV-containing regimens; (B) IFN-free RBV-containing regimens; (C) IFN-free RBV-free regimens



**Supplementary Table 1.** Comparison of adherent and non-adherent patients by treatment regimen.

|  | IFN-containing regimens |                      |        |                     |
|--|-------------------------|----------------------|--------|---------------------|
|  | Adherence $\geq$<br>80% | Adherence $<$<br>80% | p      | All patients        |
| N  | 510                     | 147                  |        | 657                 |
| Age, years                                   | 51.204 $\pm$ 10.775     | 53.558 $\pm$ 9.385   | 0.0068 | 51.731 $\pm$ 10.519 |
| Male gender                                  | 345 (67.6%)             | 96 (65.3%)           | 0.59   | 441 (67.1%)         |
| Caucasian                                    | 423 (82.9%)             | 114 (77.6%)          | 0.14   | 537 (81.7%)         |
| African-American                             | 54 (10.6%)              | 22 (15.0%)           | 0.14   | 76 (11.6%)          |
| Asian  | 19 (3.7%)               | 7 (4.8%)             | 0.57   | 26 (4.0%)           |
| Enrolled in the U.S.                         | 397 (77.8%)             | 123 (83.7%)          | 0.13   | 520 (79.1%)         |
| Employed                                     | 262 (65.5%)             | 63 (57.3%)           | 0.11   | 325 (63.7%)         |
| Cirrhosis                                    | 85 (16.7%)              | 31 (21.4%)           | 0.19   | 116 (17.7%)         |
| Treatment-naïve                              | 345 (67.6%)             | 108 (73.5%)          | 0.18   | 453 (68.9%)         |
| HCV genotype 1                               | 333 (65.9%)             | 93 (63.7%)           | 0.62   | 426 (65.4%)         |
| HCV genotype 2                               | 26 (5.1%)               | 13 (8.9%)            | 0.09   | 39 (6.0%)           |
| HCV genotype 3                               | 119 (23.6%)             | 31 (21.2%)           | 0.56   | 150 (23.0%)         |
| HCV genotypes 4, 5, 6                        | 27 (5.3%)               | 9 (6.2%)             | 0.70   | 36 (5.5%)           |
| coinfection with HIV                         | 0                       | 0                    |        | 0                   |
| baseline HCV RNA $>$ 6 log <sub>10</sub> /mL | 388 (76.1%)             | 107 (72.8%)          | 0.41   | 495 (75.3%)         |
| baseline ALT $>$ 1.5 x ULN                   | 269 (52.7%)             | 75 (51.0%)           | 0.71   | 344 (52.4%)         |
| baseline hemoglobin, g/dL                    | 14.837 $\pm$ 1.276      | 14.437 $\pm$ 1.414   | 0.0024 | 14.748 $\pm$ 1.317  |
| BMI  | 28.957 $\pm$ 5.558      | 27.671 $\pm$ 5.093   | 0.0094 | 28.670 $\pm$ 5.480  |
| History of type 2 diabetes                   | 57 (11.2%)              | 15 (10.2%)           | 0.74   | 72 (11.0%)          |
| History of anxiety                           | 67 (13.1%)              | 32 (21.8%)           | 0.0100 | 99 (15.1%)          |
| History of depression                        | 110 (21.6%)             | 32 (21.8%)           | 0.96   | 142 (21.6%)         |
| History of fatigue                           | 56 (11.0%)              | 19 (12.9%)           | 0.51   | 75 (11.4%)          |
| History of sleep disorders                   | 95 (18.6%)              | 28 (19.0%)           | 0.91   | 123 (18.7%)         |
| Baseline PROs (range)                        |                         |                      |        |                     |
| SF-36: physical functioning (0-100)          | 81.814 $\pm$ 22.874     | 75.000 $\pm$ 27.507  | 0.0169 | 80.296 $\pm$ 24.128 |
| SF-36: role physical (0-100)                 | 80.510 $\pm$ 24.978     | 71.176 $\pm$ 31.468  | 0.0085 | 78.446 $\pm$ 26.805 |
| SF-36: bodily pain (0-100)                   | 74.543 $\pm$ 24.815     | 67.843 $\pm$ 29.850  | 0.05   | 73.059 $\pm$ 26.138 |
| SF-36: general health (0-100)                | 66.682 $\pm$ 21.072     | 62.980 $\pm$ 22.850  | 0.10   | 65.855 $\pm$ 21.519 |
| SF-36: vitality (0-100)                      | 62.610 $\pm$ 22.533     | 59.574 $\pm$ 24.356  | 0.22   | 61.934 $\pm$ 22.967 |
| SF-36: social functioning (0-100)            | 82.252 $\pm$ 22.669     | 78.723 $\pm$ 28.999  | 0.79   | 81.467 $\pm$ 24.240 |
| SF-36: role emotional (0-100)                | 85.362 $\pm$ 21.689     | 79.492 $\pm$ 26.273  | 0.0283 | 84.056 $\pm$ 22.897 |
| SF-36: mental health (0-100)                 | 74.968 $\pm$ 17.934     | 73.661 $\pm$ 20.647  | 0.85   | 74.677 $\pm$ 18.563 |
| SF-36: physical component summary (25-60)    | 50.857 $\pm$ 8.814      | 48.002 $\pm$ 10.971  | 0.0130 | 50.223 $\pm$ 9.402  |
| SF-36: mental component summary (15-62)      | 50.752 $\pm$ 9.370      | 50.088 $\pm$ 11.158  | 0.90   | 50.605 $\pm$ 9.790  |
| FACIT-F: physical well-being (0-28)          | 23.422 $\pm$ 4.665      | 21.962 $\pm$ 6.175   | 0.05   | 23.108 $\pm$ 5.057  |
| FACIT-F: emotional well-being (0-24)         | 18.438 $\pm$ 4.103      | 18.657 $\pm$ 4.087   | 0.69   | 18.485 $\pm$ 4.097  |
| FACIT-F: social well-being (0-28)            | 21.603 $\pm$ 5.948      | 21.656 $\pm$ 5.355   | 0.67   | 21.614 $\pm$ 5.819  |
| FACIT-F: functional well-being (0-28)        | 20.964 $\pm$ 5.846      | 19.782 $\pm$ 6.049   | 0.05   | 20.713 $\pm$ 5.903  |
| FACIT-F: fatigue (0-52)                      | 40.283 $\pm$ 10.894     | 37.710 $\pm$ 13.484  | 0.18   | 39.725 $\pm$ 11.540 |

|  |                  |                  |         |                  |
|--|------------------|------------------|---------|------------------|
| FACIT-F: total (0-160)                   | 124.761 ± 24.966 | 119.431 ± 30.023 | 0.17    | 123.624 ± 26.187 |
| CLDQ-HCV: activity/energy (1-7)          | 5.483 ± 1.269    | 5.160 ± 1.537    | 0.09    | 5.414 ± 1.335    |
| CLDQ-HCV: emotional (1-7)                | 5.513 ± 1.119    | 5.395 ± 1.302    | 0.66    | 5.487 ± 1.160    |
| CLDQ-HCV: worry (1-7)                    | 5.428 ± 1.234    | 5.471 ± 1.336    | 0.46    | 5.437 ± 1.255    |
| CLDQ-HCV: systemic (1-7)                 | 5.258 ± 1.213    | 4.903 ± 1.405    | 0.0309  | 5.182 ± 1.263    |
| CLDQ-HCV: total (1-7)                    | 5.420 ± 1.054    | 5.232 ± 1.228    | 0.25    | 5.380 ± 1.095    |
| WPAI:SHP: work productivity (1-0)        | 0.105 ± 0.205    | 0.114 ± 0.218    | 0.69    | 0.107 ± 0.207    |
| WPAI:SHP: absenteeism (1-0)              | 0.028 ± 0.117    | 0.040 ± 0.128    | 0.12    | 0.030 ± 0.119    |
| WPAI:SHP: presenteeism (1-0)             | 0.077 ± 0.156    | 0.073 ± 0.132    | 0.91    | 0.077 ± 0.151    |
| WPAI:SHP: activity (1-0)                 | 0.143 ± 0.227    | 0.217 ± 0.296    | 0.0273  | 0.159 ± 0.245    |
| SF-6D health utility (20-100)            | 72.347 ± 14.571  | 69.454 ± 17.029  | 0.12    | 71.708 ± 15.182  |
| Treatment-related adverse events and SVR |                  |                  |         |                  |
| Blood-related and anemia                 | 55 (10.8%)       | 56 (38.1%)       | <0.0001 | 111 (16.9%)      |
| Fatigue                                  | 269 (52.7%)      | 93 (63.3%)       | 0.0239  | 362 (55.1%)      |
| Flu-like symptoms                        | 194 (38.0%)      | 61 (41.5%)       | 0.45    | 255 (38.8%)      |
| Gastrointestinal                         | 195 (38.2%)      | 82 (55.8%)       | 0.0001  | 277 (42.2%)      |
| Musculo-skeletal                         | 153 (30.0%)      | 54 (36.7%)       | 0.12    | 207 (31.5%)      |
| Nervous                                  | 212 (41.6%)      | 76 (51.7%)       | 0.0292  | 288 (43.8%)      |
| Psychiatric                              | 227 (44.5%)      | 71 (48.3%)       | 0.42    | 298 (45.4%)      |
| Skin and subcutaneous tissue             | 201 (39.4%)      | 53 (36.1%)       | 0.46    | 254 (38.7%)      |
| Other                                    | 304 (59.6%)      | 123 (83.7%)      | <0.0001 | 427 (65.0%)      |
| No adverse events                        | 50 (9.8%)        | 3 (2.0%)         | 0.0023  | 53 (8.1%)        |
| SVR-12                                   | 438 (85.9%)      | 110 (74.8%)      | 0.0015  | 548 (83.4%)      |

#### IFN-free RBV-containing regimens

| N  | 2,131          | 397            |         | 2,528          |
|--|----------------|----------------|---------|----------------|
| Age, years                                 | 51.395 ± 9.811 | 50.914 ± 9.976 | 0.23    | 51.319 ± 9.837 |
| Male gender                                | 1,385 (65.0%)  | 257 (64.7%)    | 0.92    | 1,642 (65.0%)  |
| Caucasian                                  | 1,862 (87.4%)  | 332 (83.6%)    | 0.0428  | 2,194 (86.8%)  |
| African-American                           | 169 (7.9%)     | 40 (10.1%)     | 0.15    | 209 (8.3%)     |
| Asian                                      | 52 (2.4%)      | 12 (3.0%)      | 0.50    | 64 (2.5%)      |
| Enrolled in the U.S.                       | 1,258 (59.0%)  | 207 (52.1%)    | 0.0106  | 1,465 (58.0%)  |
| Employed                                   | 1,062 (61.7%)  | 171 (51.2%)    | 0.0003  | 1,233 (60.0%)  |
| Cirrhosis                                  | 397 (18.6%)    | 71 (17.9%)     | 0.74    | 468 (18.5%)    |
| Treatment-naïve                            | 1,311 (61.5%)  | 291 (73.3%)    | <0.0001 | 1,602 (63.4%)  |
| HCV genotype 1                             | 920 (44.5%)    | 182 (47.2%)    | 0.34    | 1,102 (44.9%)  |
| HCV genotype 2                             | 353 (17.1%)    | 46 (11.9%)     | 0.0117  | 399 (16.3%)    |
| HCV genotype 3                             | 789 (38.2%)    | 158 (40.9%)    | 0.31    | 947 (38.6%)    |
| HCV genotypes 4, 5, 6                      | 5 (0.2%)       | 0 (0.0%)       | 0.33    | 5 (0.2%)       |
| coinfection with HIV                       | 353 (16.6%)    | 142 (35.8%)    | <0.0001 | 495 (19.6%)    |
| baseline HCV RNA > 6 log <sub>10</sub> /mL | 1,612 (75.6%)  | 290 (73.0%)    | 0.27    | 1,902 (75.2%)  |
| baseline ALT > 1.5 x ULN                   | 1,198 (56.2%)  | 204 (51.4%)    | 0.08    | 1,402 (55.5%)  |
| baseline hemoglobin, g/dL                  | 14.727 ± 1.293 | 14.376 ± 1.484 | <0.0001 | 14.673 ± 1.330 |
| BMI  | 27.070 ± 5.077 | 26.628 ± 4.950 | 0.13    | 27.001 ± 5.059 |
| History of type 2 diabetes                 | 198 (9.3%)     | 36 (9.1%)      | 0.89    | 234 (9.3%)     |
| History of anxiety                         | 329 (15.4%)    | 62 (15.6%)     | 0.93    | 391 (15.5%)    |
| History of depression                      | 555 (26.0%)    | 134 (33.8%)    | 0.0015  | 689 (27.3%)    |
| History of fatigue                         | 257 (12.1%)    | 37 (9.3%)      | 0.12    | 294 (11.6%)    |

|   |                  |                  |         |                  |
|---|------------------|------------------|---------|------------------|
| History of sleep disorders                | 401 (18.8%)      | 74 (18.6%)       | 0.93    | 475 (18.8%)      |
| Baseline PROs (range)                     |                  |                  |         |                  |
| SF-36: physical functioning (0-100)       | 82.378 ± 21.751  | 78.487 ± 24.988  | 0.0163  | 81.758 ± 22.338  |
| SF-36: role physical (0-100)              | 77.078 ± 26.279  | 72.166 ± 28.281  | 0.0020  | 76.298 ± 26.662  |
| SF-36: bodily pain (0-100)                | 72.617 ± 25.487  | 68.717 ± 27.279  | 0.0156  | 71.999 ± 25.813  |
| SF-36: general health (0-100)             | 63.551 ± 22.135  | 60.932 ± 22.119  | 0.0376  | 63.138 ± 22.149  |
| SF-36: vitality (0-100)                   | 60.772 ± 22.896  | 58.128 ± 22.576  | 0.0285  | 60.358 ± 22.861  |
| SF-36: social functioning (0-100)         | 79.872 ± 24.887  | 73.669 ± 26.429  | <0.0001 | 78.886 ± 25.235  |
| SF-36: role emotional (0-100)             | 81.682 ± 23.954  | 76.356 ± 26.532  | 0.0002  | 80.839 ± 24.452  |
| SF-36: mental health (0-100)              | 72.862 ± 18.653  | 68.533 ± 20.357  | 0.0004  | 72.187 ± 18.990  |
| SF-36: physical component summary (25-60) | 50.547 ± 8.662   | 49.238 ± 9.267   | 0.0133  | 50.346 ± 8.768   |
| SF-36: mental component summary (15-62)   | 49.267 ± 10.309  | 47.190 ± 11.124  | 0.0016  | 48.948 ± 10.462  |
| FACIT-F: physical well-being (0-28)       | 23.481 ± 4.993   | 22.557 ± 5.479   | 0.0022  | 23.334 ± 5.084   |
| FACIT-F: emotional well-being (0-24)      | 18.180 ± 4.239   | 17.807 ± 4.332   | 0.17    | 18.120 ± 4.256   |
| FACIT-F: social well-being (0-28)         | 21.067 ± 6.331   | 19.321 ± 7.017   | <0.0001 | 20.789 ± 6.475   |
| FACIT-F: functional well-being (0-28)     | 20.138 ± 6.078   | 19.047 ± 6.366   | 0.0039  | 19.963 ± 6.136   |
| FACIT-F: fatigue (0-52)                   | 39.381 ± 11.470  | 37.422 ± 12.175  | 0.0050  | 39.065 ± 11.606  |
| FACIT-F: total (0-160)                    | 122.312 ± 26.989 | 116.162 ± 28.590 | 0.0002  | 121.331 ± 27.336 |
| CLDQ-HCV: activity/energy (1-7)           | 5.341 ± 1.335    | 5.138 ± 1.433    | 0.0284  | 5.309 ± 1.353    |
| CLDQ-HCV: emotional (1-7)                 | 5.419 ± 1.195    | 5.222 ± 1.276    | 0.0118  | 5.387 ± 1.210    |
| CLDQ-HCV: worry (1-7)                     | 5.519 ± 1.243    | 5.411 ± 1.243    | 0.09    | 5.502 ± 1.243    |
| CLDQ-HCV: systemic (1-7)                  | 5.093 ± 1.287    | 4.872 ± 1.335    | 0.0052  | 5.058 ± 1.297    |
| CLDQ-HCV: total (1-7)                     | 5.343 ± 1.118    | 5.165 ± 1.168    | 0.0103  | 5.315 ± 1.128    |
| WPAI:SHP: work productivity (1-0)         | 0.115 ± 0.215    | 0.119 ± 0.201    | 0.60    | 0.116 ± 0.214    |
| WPAI:SHP: absenteeism (1-0)               | 0.030 ± 0.129    | 0.024 ± 0.092    | 0.80    | 0.030 ± 0.125    |
| WPAI:SHP: presenteeism (1-0)              | 0.086 ± 0.161    | 0.094 ± 0.155    | 0.40    | 0.087 ± 0.160    |
| WPAI:SHP: activity (1-0)                  | 0.175 ± 0.253    | 0.190 ± 0.257    | 0.33    | 0.177 ± 0.254    |
| SF-6D health utility (20-100)             | 70.595 ± 14.380  | 67.319 ± 13.555  | 0.0001  | 70.095 ± 14.303  |
| Treatment-related adverse events and SVR  |                  |                  |         |                  |
| Blood-related and anemia                  | 131 (6.1%)       | 94 (23.7%)       | <0.0001 | 225 (8.9%)       |
| Fatigue                                   | 770 (36.1%)      | 171 (43.1%)      | 0.0086  | 941 (37.2%)      |
| Flu-like symptoms                         | 68 (3.2%)        | 11 (2.8%)        | 0.66    | 79 (3.1%)        |
| Gastrointestinal                          | 564 (26.5%)      | 117 (29.5%)      | 0.22    | 681 (26.9%)      |
| Musculo-skeletal                          | 238 (11.2%)      | 44 (11.1%)       | 0.96    | 282 (11.2%)      |
| Nervous                                   | 531 (24.9%)      | 106 (26.7%)      | 0.45    | 637 (25.2%)      |
| Psychiatric                               | 593 (27.8%)      | 110 (27.7%)      | 0.96    | 703 (27.8%)      |
| Skin and subcutaneous tissue              | 486 (22.8%)      | 98 (24.7%)       | 0.41    | 584 (23.1%)      |
| Other                                     | 583 (27.4%)      | 144 (36.3%)      | 0.0003  | 727 (28.8%)      |
| No adverse events                         | 657 (30.8%)      | 87 (21.9%)       | 0.0003  | 744 (29.4%)      |
| SVR-12                                    | 1,819 (85.4%)    | 314 (79.1%)      | 0.0016  | 2,133 (84.4%)    |

#### IFN-free RBV-free regimens

| N                | 1,436          | 57              |      | 1,493          |
|------------------|----------------|-----------------|------|----------------|
| Age, years       | 53.394 ± 9.638 | 51.509 ± 10.984 | 0.38 | 53.322 ± 9.695 |
| Male gender      | 969 (67.5%)    | 35 (61.4%)      | 0.34 | 1,004 (67.2%)  |
| Caucasian        | 1,107 (77.1%)  | 41 (71.9%)      | 0.36 | 1,148 (76.9%)  |
| African-American | 289 (20.1%)    | 13 (22.8%)      | 0.62 | 302 (20.2%)    |
| Asian            | 21 (1.5%)      | 0 (0.0%)        | 0.36 | 21 (1.4%)      |

|  |                     |                     |         |                  |
|--|---------------------|---------------------|---------|------------------|
| Enrolled in the U.S.                       | 1,147 (79.9%)       | 49 (86.0%)          | 0.26    | 1,196 (80.1%)    |
| Employed                                   | 863 (60.5%)         | 24 (44.4%)          | 0.0180  | 887 (59.9%)      |
| Cirrhosis                                  | 245 (17.1%)         | 11 (19.3%)          | 0.67    | 256 (17.2%)      |
| Treatment-naïve                            | 968 (67.4%)         | 44 (77.2%)          | 0.12    | 1,012 (67.8%)    |
| HCV genotype 1                             | 1,426 (99.9%)       | 54 (94.7%)          | <0.0001 | 1,480 (99.7%)    |
| HCV genotype 2                             | 0                   | 0                   |         | 0                |
| HCV genotype 3                             | 0                   | 0                   |         | 0                |
| HCV genotypes 4, 5, 6                      | 2 (0.1%)            | 3 (5.3%)            | <0.0001 | 5 (0.3%)         |
| coinfection with HIV                       | 319 (22.2%)         | 16 (28.1%)          | 0.30    | 335 (22.4%)      |
| baseline HCV RNA > 6 log <sub>10</sub> /mL | 1,204 (83.8%)       | 47 (82.5%)          | 0.78    | 1,251 (83.8%)    |
| baseline ALT > 1.5 x ULN                   | 692 (48.2%)         | 30 (52.6%)          | 0.51    | 722 (48.4%)      |
| baseline hemoglobin, g/dL                  | 14.740 ± 1.386      | 14.374 ± 1.204      | 0.06    | 14.726 ± 1.381   |
| BMI  | 27.276 ± 4.980      | 27.970 ± 5.653      | 0.46    | 27.302 ± 5.007   |
| History of type 2 diabetes                 | 169 (11.8%)         | 8 (14.0%)           | 0.60    | 177 (11.9%)      |
| History of anxiety                         | 290 (20.2%)         | 12 (21.1%)          | 0.87    | 302 (20.2%)      |
| History of depression                      | 397 (27.6%)         | 22 (38.6%)          | 0.07    | 419 (28.1%)      |
| History of fatigue                         | 200 (13.9%)         | 3 (5.3%)            | 0.06    | 203 (13.6%)      |
| History of sleep disorders                 | 310 (21.6%)         | 13 (22.8%)          | 0.83    | 323 (21.6%)      |
| Baseline PROs (range)                      |                     |                     |         |                  |
| SF-36: physical functioning (0-100)        | 80.672 ± 24.133     | 74.218 ± 27.547     | 0.17    | 80.436 ± 24.285  |
| SF-36: role physical (0-100)               | 76.622 ± 27.781     | 75.490 ± 28.854     | 0.77    | 76.582 ± 27.809  |
| SF-36: bodily pain (0-100)                 | 72.531 ± 25.688     | 71.679 ± 27.241     | 0.88    | 72.500 ± 25.736  |
| SF-36: general health (0-100)              | 65.613 ± 22.022     | 63.637 ± 22.105     | 0.45    | 65.542 ± 22.021  |
| SF-36: vitality (0-100)                    | 61.153 ± 23.241     | 55.896 ± 24.404     | 0.10    | 60.964 ± 23.296  |
| SF-36: social functioning (0-100)          | 80.182 ± 25.063     | 75.472 ± 29.105     | 0.44    | 80.014 ± 25.222  |
| SF-36: role emotional (0-100)              | 81.400 ± 25.516     | 78.922 ± 26.265     | 0.60    | 81.314 ± 25.538  |
| SF-36: mental health (0-100)               | 73.655 ± 19.024     | 69.811 ± 20.684     | 0.13    | 73.516 ± 19.092  |
| SF-36: physical component summary (25-60)  | 50.267 ± 9.085      | 49.655 ± 10.031     | 0.97    | 50.245 ± 9.117   |
| SF-36: mental component summary (15-62)    | 49.654 ± 10.432     | 48.079 ± 10.791     | 0.19    | 49.599 ± 10.445  |
| FACIT-F: physical well-being (0-28)        | 23.281 ± 5.264      | 22.059 ± 5.572      | 0.0451  | 23.238 ± 5.278   |
| FACIT-F: emotional well-being (0-24)       | 18.411 ± 4.318      | 17.529 ± 4.388      | 0.11    | 18.381 ± 4.322   |
| FACIT-F: social well-being (0-28)          | 21.153 ± 6.220      | 20.741 ± 6.688      | 0.77    | 21.139 ± 6.235   |
| FACIT-F: functional well-being (0-28)      | 20.344 ± 6.056      | 18.712 ± 7.395      | 0.17    | 20.286 ± 6.112   |
| FACIT-F: fatigue (0-52)                    | 39.097 ± 12.035     | 35.798 ± 12.704     | 0.06    | 38.976 ± 12.071  |
| FACIT-F: total (0-160)                     | 122.386 ±<br>27.559 | 115.134 ±<br>30.163 | 0.09    | 122.130 ± 27.677 |
| CLDQ-HCV: activity/energy (1-7)            | 5.369 ± 1.375       | 5.093 ± 1.516       | 0.21    | 5.359 ± 1.381    |
| CLDQ-HCV: emotional (1-7)                  | 5.471 ± 1.216       | 5.192 ± 1.305       | 0.09    | 5.461 ± 1.220    |
| CLDQ-HCV: worry (1-7)                      | 5.530 ± 1.278       | 5.306 ± 1.383       | 0.25    | 5.522 ± 1.282    |
| CLDQ-HCV: systemic (1-7)                   | 5.087 ± 1.279       | 4.777 ± 1.379       | 0.10    | 5.076 ± 1.283    |
| CLDQ-HCV: total (1-7)                      | 5.365 ± 1.142       | 5.092 ± 1.264       | 0.13    | 5.355 ± 1.147    |
| WPAI:SHP: work productivity (1-0)          | 0.097 ± 0.193       | 0.125 ± 0.197       | 0.57    | 0.098 ± 0.193    |
| WPAI:SHP: absenteeism (1-0)                | 0.022 ± 0.113       | 0.000 ± 0.000       | 0.25    | 0.022 ± 0.111    |
| WPAI:SHP: presenteeism (1-0)               | 0.075 ± 0.144       | 0.125 ± 0.197       | 0.39    | 0.076 ± 0.146    |
| WPAI:SHP: activity (1-0)                   | 0.176 ± 0.264       | 0.215 ± 0.278       | 0.23    | 0.177 ± 0.265    |
| SF-6D health utility (20-100)              | 71.106 ± 15.038     | 68.660 ± 14.070     | 0.23    | 71.019 ± 15.006  |
| Treatment-related adverse events and SVR   |                     |                     |         |                  |
| Blood-related and anemia                   | 4 (0.3%)            | 0 (0.0%)            | 0.69    | 4 (0.3%)         |
| Fatigue                                    | 274 (19.1%)         | 13 (22.8%)          | 0.48    | 287 (19.2%)      |

|                              |               |            |         |               |
|------------------------------|---------------|------------|---------|---------------|
| Flu-like symptoms            | 17 (1.2%)     | 3 (5.3%)   | 0.0086  | 20 (1.3%)     |
| Gastrointestinal             | 261 (18.2%)   | 12 (21.1%) | 0.58    | 273 (18.3%)   |
| Musculo-skeletal             | 91 (6.3%)     | 6 (10.5%)  | 0.21    | 97 (6.5%)     |
| Nervous                      | 304 (21.2%)   | 9 (15.8%)  | 0.33    | 313 (21.0%)   |
| Psychiatric                  | 167 (11.6%)   | 5 (8.8%)   | 0.51    | 172 (11.5%)   |
| Skin and subcutaneous tissue | 106 (7.4%)    | 5 (8.8%)   | 0.69    | 111 (7.4%)    |
| Other                        | 158 (11.0%)   | 11 (19.3%) | 0.05    | 169 (11.3%)   |
| No adverse events            | 764 (53.2%)   | 29 (50.9%) | 0.73    | 793 (53.1%)   |
| SVR-12                       | 1,395 (97.1%) | 47 (82.5%) | <0.0001 | 1,442 (96.6%) |

---



